Sarah Arbe‐Barnes

1.7k total citations · 1 hit paper
16 papers, 880 citations indexed

About

Sarah Arbe‐Barnes is a scholar working on Public Health, Environmental and Occupational Health, Pharmacology and Oncology. According to data from OpenAlex, Sarah Arbe‐Barnes has authored 16 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Public Health, Environmental and Occupational Health, 7 papers in Pharmacology and 3 papers in Oncology. Recurrent topics in Sarah Arbe‐Barnes's work include Malaria Research and Control (10 papers), Drug-Induced Hepatotoxicity and Protection (6 papers) and Trypanosoma species research and implications (2 papers). Sarah Arbe‐Barnes is often cited by papers focused on Malaria Research and Control (10 papers), Drug-Induced Hepatotoxicity and Protection (6 papers) and Trypanosoma species research and implications (2 papers). Sarah Arbe‐Barnes collaborates with scholars based in Switzerland, United States and United Kingdom. Sarah Arbe‐Barnes's co-authors include Sergio Wittlin, Susan A. Charman, Jonathan L. Vennerstrom, Stephan Duparc, Christian Scheurer, Reto Brun, Hugues Matile, Heinrich Urwyler, Maniyan P. Padmanilayam and Yuanqing Tang and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

Sarah Arbe‐Barnes

13 papers receiving 859 citations

Hit Papers

Identification of an antimalarial synthetic trioxolane dr... 2004 2026 2011 2018 2004 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Identification of an antimalarial synthetic trioxolane drug development candidate
    2004 507 citations Jonathan L. Vennerstrom, Sarah Arbe‐Barnes et al. Nature profile →

Peers

Sarah Arbe‐Barnes
John Okombo South Africa
Joël Mosnier France
Philip J. Rosenthal United States
Rémy Amalvict France
Victoria Barton United Kingdom
Barbara Kotecka Australia
Mark Baker Switzerland
Steven R. Meshnick United States
Victor Meléndez United States
Trupti Pandharkar United States
John Okombo South Africa
Sarah Arbe‐Barnes
Citations per year, relative to Sarah Arbe‐Barnes Sarah Arbe‐Barnes (= 1×) peers John Okombo

Countries citing papers authored by Sarah Arbe‐Barnes

Since Specialization
Citations

This map shows the geographic impact of Sarah Arbe‐Barnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Arbe‐Barnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Arbe‐Barnes more than expected).

Fields of papers citing papers by Sarah Arbe‐Barnes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Arbe‐Barnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Arbe‐Barnes. The network helps show where Sarah Arbe‐Barnes may publish in the future.

Co-authorship network of co-authors of Sarah Arbe‐Barnes

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Arbe‐Barnes. A scholar is included among the top collaborators of Sarah Arbe‐Barnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Arbe‐Barnes. Sarah Arbe‐Barnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
3.
Groger, Mirjam, Serge-Brice Assi, Jude D. Bigoga, et al.. (2023). Community health workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries. International Journal of Infectious Diseases. 137. 114–117.
4.
Chandiwana, Nomathemba, Hilary Johnstone, Chung Ju, et al.. (2022). Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. EBioMedicine. 86. 104322–104322. 12 indexed citations
5.
Groger, Mirjam, Ghyslain Mombo‐Ngoma, Rella Zoleko Manego, et al.. (2022). Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial. The Lancet Microbe. 3(8). e598–e605. 8 indexed citations
6.
Mombo‐Ngoma, Ghyslain, Serge-Brice Assi, Jude D. Bigoga, et al.. (2021). Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study. PLoS Medicine. 18(6). e1003669–e1003669. 20 indexed citations
7.
Hachizovu, Sebastian, Alieu Mendy, Mamadou Ousmane Ndiath, et al.. (2021). Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial. Clinical Infectious Diseases. 74(2). 180–188. 3 indexed citations
8.
Banerji, Udai, Andra Curcean, Nigel Bush, et al.. (2021). Phase I trial of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study).. Journal of Clinical Oncology. 39(15_suppl). TPS3145–TPS3145. 7 indexed citations
9.
10.
Garcia‐Manero, Guillermo, Guillermo Montalban‐Bravo, Hui Yang, et al.. (2016). A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. Blood. 128(22). 227–227. 22 indexed citations
11.
Morris, Carrie A., Rolf Pokorny, Luis López Lázaro, et al.. (2014). Pharmacokinetic Interaction between Pyronaridine-Artesunate and Metoprolol. Antimicrobial Agents and Chemotherapy. 58(10). 5900–5908. 13 indexed citations
12.
Duparc, Stephan, Isabelle Borghini-Fuhrer, Sarah Arbe‐Barnes, et al.. (2013). Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malaria Journal. 12(1). 70–70. 56 indexed citations
13.
Croft, Simon L., Stephan Duparc, Sarah Arbe‐Barnes, et al.. (2012). Review of pyronaridine anti-malarial properties and product characteristics. Malaria Journal. 11(1). 270–270. 106 indexed citations
14.
Moehrle, Joerg J., Stephan Duparc, Christoph Siethoff, et al.. (2012). First‐in‐man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. British Journal of Clinical Pharmacology. 75(2). 535–548. 78 indexed citations
15.
Kocken, Clemens H. M., Annemarie Voorberg-van der Wel, Sarah Arbe‐Barnes, et al.. (2006). Plasmodium vivax: In vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. Experimental Parasitology. 113(3). 197–200. 17 indexed citations
16.
Vennerstrom, Jonathan L., Sarah Arbe‐Barnes, Reto Brun, et al.. (2004). Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 430(7002). 900–904. 507 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Okombo Breakdown of academic impact, for papers by Joël Mosnier Breakdown of academic impact, for papers by Philip J. Rosenthal Breakdown of academic impact, for papers by Rémy Amalvict Breakdown of academic impact, for papers by Victoria Barton Breakdown of academic impact, for papers by Barbara Kotecka Breakdown of academic impact, for papers by Mark Baker Breakdown of academic impact, for papers by Steven R. Meshnick Breakdown of academic impact, for papers by Victor Meléndez Breakdown of academic impact, for papers by Trupti Pandharkar
Rankless by CCL
2026